Ann Dermatol.  2012 Aug;24(3):295-305. 10.5021/ad.2012.24.3.295.

The Efficacy and Safety of 17alpha-Estradiol (Ell-Cranell(R) alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

Affiliations
  • 1Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. leewonsoo@yonsei.ac.kr

Abstract

BACKGROUND
There are several commercially available agents to treat female pattern hair loss (FPHL), including minoxidil solution, anti-androgen agents and mineral supplements. However, these treatments are not always satisfactory. We report the results of a clinical trial of 17alpha-estradiol (Ell-Cranell(R) alpha 0.025%) solution to Korean female patients with FPHL.
OBJECTIVE
This study was designed to examine the efficacy and safety of Ell-Cranell(R) alpha 0.025% solution in Korean female patients with FPHL.
METHODS
A total of 53 women, 18 to 55 years old, applied topical Ell-Cranell(R) alpha 0.025% solution once daily for 8 months. Efficacy was evaluated by the change of hair counts and diameter, subjective assessment, and photographic assessment by investigators.
RESULTS
Hair counts and diameter from baseline to 4 and 8 months after treatment increased in treated patients and these changes were statistically significant (p<0.0001). 17alpha-estradiol (Ell-Cranell(R) alpha 0.025%) solution showed significant improvement by subjective self-assessment and by investigator photographic assessment. Ell-Cranell(R) alpha 0.025% solution was well tolerated over 8-months period.
CONCLUSION
This study showed that Ell-Cranell(R) alpha 0.025% solution is a safe and effective agent for Korean women with FPHL.

Keyword

17alpha-estradiol; Ell-Cranell(R); Female pattern hair loss

MeSH Terms

Female
Hair
Humans
Minoxidil
Research Personnel
Self-Assessment
Minoxidil

Figure

  • Fig. 1 Hair counts from baseline to 4, 8 months after treatment were increased in treated patients, statistically significant (p<0.0001). SD: standard deviation, Min: minimum, max: maximum, CI: confidence internal.

  • Fig. 2 Hair diameter from baseline to 4, 8 months after treatment were increased in treated patients, statistically significant (p<0.0001). SD: standard deviation, Min: minimum, max: maximum, CI: confidence interval.

  • Fig. 3 Effectiveness of hair regrowth in patients with female pattern hair loss after 8 months treatment. Pt: patient.

  • Fig. 4 Investigator assessment of clinical response by duration of the treatment. 17α-estradiol (Ell-Cranell® alpha 0.025%) solution showed significant improvement by investigator photographic assessment.


Cited by  1 articles

Characteristics of Androgenetic Alopecia in Asian
Won-Soo Lee, Hae-Jin Lee
Ann Dermatol. 2012;24(3):243-252.    doi: 10.5021/ad.2012.24.3.243.


Reference

1. Sinclair R. Male pattern androgenetic alopecia. BMJ. 1998. 317:865–869.
2. Venning VA, Dawber RP. Patterned androgenic alopecia in women. J Am Acad Dermatol. 1988. 18:1073–1077.
Article
3. Paik JH, Yoon JB, Sim WY, Kim BS, Kim NI. The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol. 2001. 145:95–99.
Article
4. Shin HS, Lee SH, Kim DH, An JS, Kwon OS, Eun HC, et al. The efficacy and safety of AP-FHG0604T on female pattern hair loss: a randomized double-blind placebo-controlled clinical trial. Korean J Dermatol. 2007. 45:119–126.
5. Blume-Peytavi U, Kunte C, Krisp A, Garcia Bartels N, Ellwanger U, Hoffmann R. Comparison of the efficacy and safety of topical minoxidil and topical alfatradiol in the treatment of androgenetic alopecia in women. J Dtsch Dermatol Ges. 2007. 5:391–395.
Article
6. Münster U, Hammer S, Blume-Peytavi U, Schäfer-Korting M. Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride. Skin Pharmacol Appl Skin Physiol. 2003. 16:356–366.
Article
7. Hoffmann R, Niiyama S, Huth A, Kissling S, Happle R. 17alpha-estradiol induces aromatase activity in intact human anagen hair follicles ex vivo. Exp Dermatol. 2002. 11:376–380.
Article
8. Arai A, von Hintzenstern J, Kiesewetter F, Schell H, Hornstein OP. In vitro effects of testosterone, dihydrotestosterone and estradiol on cell growth of human hair bulb papilla cells and hair root sheath fibroblasts. Acta Derm Venereol. 1990. 70:338–341.
9. Lee WS, Ro BI, Hong SP, Bak H, Sim WY, Kim do W, et al. A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. J Am Acad Dermatol. 2007. 57:37–46.
Article
10. Lew BL, Sim WY, Huh CH, Park JK. Clinical trial to evaluate the safety and efficacy of scalp med(R) in treatment of patients with androgenetic alopecia. Korean J Dermatol. 2008. 46:776–783.
11. Kantor J, Kessler LJ, Brooks DG, Cotsarelis G. Decreased serum ferritin is associated with alopecia in women. J Invest Dermatol. 2003. 121:985–988.
Article
12. Messenger AG. Thyroid hormone and hair growth. Br J Dermatol. 2000. 142:633–634.
Article
13. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern hair loss with oral antiandrogens. Br J Dermatol. 2005. 152:466–473.
Article
14. Hoffmann R. Steroidogenic isoenzymes in human hair and their potential role in androgenetic alopecia. Dermatology. 2003. 206:85–95.
Article
15. Hoffmann R. Enzymology of the hair follicle. Eur J Dermatol. 2001. 11:296–300.
16. Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC. Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness. J Dermatol Sci. 2004. 34:11–16.
Article
17. Zouboulis CC, Degitz K. Androgen action on human skin - from basic research to clinical significance. Exp Dermatol. 2004. 13:Suppl 4. 5–10.
Article
18. Meisheri KD, Cipkus LA, Taylor CJ. Mechanism of action of minoxidil sulfate-induced vasodilation: a role for increased K+ permeability. J Pharmacol Exp Ther. 1988. 245:751–760.
19. Olsen EA. Olsen EA, editor. Androgenetic alopecia. Disorders of hair growth: diagnosis and treatment. 1994. New York: McGraw-Hill;257–283.
20. Yun SK, Kim HY, Ihm CW. Plasma levels of dehydroepiandrosterone sulfate (DHEA-S) and total testosterone in the patients with female androgenetic alopecia. Korean J Dermatol. 1995. 33:1060–1065.
21. Sawaya ME, Price VH. Different levels of 5alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol. 1997. 109:296–300.
Article
22. Wozel G, Naranayan S, Jäckel A, Lutz GA. Alfatradiol (0,025%) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern. Akt Dermatol. 2005. 31:553–560.
Article
23. Orfanos CE, Vogels L. Local therapy of androgenetic alopecia with 17 alpha-estradiol. A controlled, randomized double-blind study (author's transl). Dermatologica. 1980. 161:124–132.
24. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004. 50:541–553.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr